VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Reformation Files for NYSE IPO Off 20 Growth Quarters
Value Add VC/Pulse/IPOup to $1B target valuation

Reformation Files for NYSE IPO Off 20 Growth Quarters

Sustainable womenswear brand Reformation filed an amended S-1 for a proposed NYSE listing under ticker REF, off 20 straight quarters of double-digit growth, targeting up to a $1 billion valuation.

By the Numbers

$507.1M
2025 revenue
+30.4% YoY
Q1 2026 growth
20 quarters
Growth streak
up to $1B
Target valuation
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 23, 2026
2 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Reformation filed a registration statement to list on the NYSE under ticker 'REF,' with J.P. Morgan and Morgan Stanley as lead bookrunners alongside Citigroup, RBC Capital Markets, Guggenheim Securities and others

2

Revenue for fiscal 2025 rose to $507.1 million from $438.2 million a year earlier, and Q1 2026 net revenue grew 30.4% year-over-year to $112.3 million, extending a streak of 20 consecutive quarters of double-digit growth

3

Net profit actually declined to $12.6 million in 2025 from $33 million the prior year even as revenue grew, a detail that complicates the otherwise-clean growth story and will draw scrutiny during the roadshow

4

The IPO includes 14,062,500 shares and targets up to a $1 billion valuation, positioning Reformation as a rare profitable, direct-to-consumer retail brand going public in a market otherwise dominated by AI and infrastructure listings

TC

The VC Read · Trace's Take

Trace Cohen

20 straight quarters of double-digit growth and shrinking profit in the same filing is the real story here, not the ticker symbol -- public investors are about to find out whether they still reward a growth story that's spending its way through margin. A consumer retail brand actually filing for NYSE this year, when every other headline IPO is AI infrastructure, is worth watching as a test of whether appetite for non-AI growth stories has actually returned or just looks that way in a press release.

Tech IPO Tracker →

Analysis

Reformation, the sustainable womenswear brand, filed a registration statement with the SEC for a proposed initial public offering on the New York Stock Exchange under ticker 'REF,' with J.P. Morgan and Morgan Stanley serving as lead bookrunning managers alongside Citigroup, RBC Capital Markets, Guggenheim Securities, Baird, William Blair, BTIG and Telsey Advisory Group. The IPO includes 14,062,500 shares of common stock, and the company is reportedly targeting a valuation of up to $1 billion.

The growth numbers underlying the filing are genuinely strong: revenue for fiscal 2025 rose to $507.1 million from $438.2 million the prior year, and first-quarter 2026 net revenue grew 30.4% year-over-year to $112.3 million, extending a run of 20 consecutive quarters of double-digit growth -- a remarkably consistent streak for a direct-to-consumer apparel brand in a retail environment that's punished plenty of DTC peers.

The complicating detail is profitability: net profit actually declined to $12.6 million in 2025 from $33 million the year prior, even as revenue grew nearly 16%. That divergence -- strong top-line growth paired with shrinking bottom-line profit -- will draw real scrutiny during the roadshow, since it suggests rising costs, likely from store expansion, marketing, or supply-chain investment, are outpacing revenue gains for now.

“The complicating detail is profitability: net profit actually declined to $12.6 million in 2025 from $33 million the year prior, even as revenue grew nearly 16%.”

Reformation's listing is notable in context: it's one of the only consumer retail brands going public amid an IPO pipeline otherwise dominated by AI infrastructure, chip and SPAC listings. Its closest public comparables are more limited than a typical DTC apparel IPO would have a decade ago, given how few pure-play sustainable-fashion brands have gone public at scale -- making Reformation something of a standalone test case for whether public investors still reward a profitable-at-times, mission-branded retail story in a market currently obsessed with AI multiples.

For consumer and retail investors, Reformation is a useful signal that IPO-market appetite hasn't narrowed entirely to AI and infrastructure names -- a DTC brand with 20 straight quarters of double-digit growth can still find a path to NYSE, even if the declining-profit detail means it likely won't command the kind of premium multiple AI-adjacent listings are getting this year. The risk is straightforward: consumer discretionary spending is more macro-sensitive than enterprise software or AI infrastructure, and Reformation's growth streak has yet to be tested against a genuine consumer spending pullback.

Watch for: the eventual share price range and how the market prices the tension between Reformation's growth streak and its declining profit; how the stock trades relative to comparable DTC and sustainable-brand public peers; and whether other consumer retail brands follow Reformation's lead in testing public-market appetite outside the AI-infrastructure theme dominating this year's IPO pipeline.

ShareXLinkedInEmail

More on

Reformation →

Reported by PR Newswire · First reported by SEC EDGAR · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com